{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-023908","form_type":"8-K","ticker":"ABEO","cik":"0000318306","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2023-07-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.248767+00:00","generated_at":"2026-06-13T11:20:53.833437+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Abeona closes $25M direct offering; proceeds to fund EB-101 commercialization","bullets":["Gross proceeds of $25M from sale of 3.28M shares and 2.92M pre-funded warrants at $4.03 per share.","Offering led by Nantahala Capital Management with participation by Adage Capital Partners and other existing investors.","Net proceeds to fund commercialization of EB-101 and extend cash runway into Q4 2024.","Company expects to qualify for a priority review voucher upon potential BLA approval in H1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-023908","json":"https://secwatch.observer/filing/0001493152-23-023908.json","markdown":"https://secwatch.observer/filing/0001493152-23-023908.md","text":"https://secwatch.observer/filing/0001493152-23-023908.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/318306/000149315223023908/0001493152-23-023908-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/318306/000149315223023908/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T11:20:53.833437+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}